title: Safety of intravenous ciprofloxacin. A review.
abstract: Data from 1,878 courses of intravenous ciprofloxacin therapy, administered to 1,869 patients in 59 clinical trials, were analyzed for drug safety. The 985 men and 884 women had a mean age of 50 years, and more than one third were over 60 years of age. An overwhelming majority had at least one accompanying systemic illness, and the condition of more than half the patients was only fair or poor at the onset of therapy. Ciprofloxacin was administered in a unit dose of either 200 mg (68 percent of the patients) or 300 mg (28 percent) by intravenous infusion, generally over 30 minutes every 12 hours, at a mean daily dosage of 456 mg. The duration of intravenous therapy ranged from one to 57 days, with a mean of seven days; over 1,000 patients were treated for more than five days. Adverse events considered probably or possibly related to intravenous ciprofloxacin were reported in 15.8 percent of the courses; therapy was discontinued prematurely in 3 percent. Local reactions at the site of infusion were the most common, occurring in 4.4 percent of the courses. Changes in blood chemistry values (4.1 percent) included increases in alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase. Reports of adverse effects referable to the gastrointestinal tract (3.0 percent) were primarily nausea and diarrhea. Central nervous system reactions (1.8 percent) included convulsive seizures, headache, and dizziness. In comparative trials, events considered probably or possibly drug related were reported for 17.3 and 13.6 percent of the ciprofloxacin- and ceftazidime-treated patients, respectively. The incidence of adverse events other than local reactions at the infusion site was not significantly different between the ciprofloxacin- and ceftazidime-treated patients (12.7 percent versus 11.0 percent, p greater than 0.2).
authors.affiliation: Miles Inc., Pharmaceutical Division, West Haven, Connecticut 06516.
authors.forename: G M
authors.initials: GM
authors.lastname: Arcieri
authors.forename: N
authors.initials: N
authors.lastname: Becker
authors.forename: B
authors.initials: B
authors.lastname: Esposito
authors.forename: E
authors.initials: E
authors.lastname: Griffith
authors.forename: A
authors.initials: A
authors.lastname: Heyd
authors.forename: C
authors.initials: C
authors.lastname: Neumann
authors.forename: B
authors.initials: B
authors.lastname: O'Brien
authors.forename: P
authors.initials: P
authors.lastname: Schacht
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001424:Bacterial Infections / Q000188:drug therapy; D002442:Ceftazidime / Q000009:adverse effects; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D012449:Safety
chemical_list: D002939:Ciprofloxacin; D002442:Ceftazidime